SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 6990.
  • 2
    DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin 2011; 61: 40918.
  • 3
    O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005; 10(Suppl 3): 209.
  • 4
    McAllister SS, Gifford AM, Greiner AL et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008; 133: 9941005.
  • 5
    Elkabets M, Gifford AM, Scheel C et al. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 2011; 121: 78499.
  • 6
    Kuznetsov HS, Marsh T, Markens BA et al. Identification of luminal breast cancers that establish a tumor supportive macroenvironment defined by pro-angiogenic platelets and bone marrow derived cells. Cancer Discov 2012; 2: 115065.
  • 7
    Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790800.
  • 8
    Solomayer EF, Diel IJ, Krempien B et al. Results of iliac crest biopsies taken from 1465 patients with primary breast cancer. J Cancer Res Clin Oncol 1998; 124: 448.
  • 9
    Diel IJ, Kaufmann M, Costa SD et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88: 16528.
  • 10
    Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 74752.
  • 11
    Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 1086974.
  • 12
    Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 103938.
  • 13
    Stephens PJ, Tarpey PS, Davies H et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486: 4004.
  • 14
    Sanpaolo P, Barbieri V, Genovesi D. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. Eur J Surg Oncol 2011; 37: 87682.
  • 15
    Kuo WH, Chang YY, Lai LC et al. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. PLoS ONE 2012; 7: e45831.
  • 16
    de Ronde JJ, Hannemann J, Halfwerk H et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 2009; 119: 11926.
  • 17
    Leary RJ, Sausen M, Kinde I et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012; 4: 162ra54.
  • 18
    Serrano MJ, Rovira PS, Martinez-Zubiaurre I, Rodriguez MD, Fernandez M, Lorente JA. Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. Exp Ther Med 2012; 4: 438.
  • 19
    Boutrus RR, Abi Raad RF, Kuter I et al. Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy. Int J Biol Markers 2013; 28: e17e23.
  • 20
    Munzone E, Botteri E, Sandri MT et al. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clin Breast Cancer 2012; 12: 3406.
  • 21
    Gainer SM, Lodhi AK, Bhattacharyya A, Krishnamurthy S, Kuerer HM, Lucci A. Invasive lobular carcinoma predicts micrometastasis in breast cancer. J Surg Res 2012; 177: 936.
  • 22
    Krishnamurthy S, Cristofanilli M, Singh B et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 2010; 116: 33307.
  • 23
    Macfarlane R, Seal M, Speers C et al. Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist 2012; 17: 1728.
  • 24
    Lindstrom LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30: 26018.
  • 25
    de Albuquerque A, Kubisch I, Ernst D et al. Development of a molecular multimarker assay for the analysis of circulating tumor cells in adenocarcinoma patients. Clin Lab 2012; 58: 37384.
  • 26
    Fehm T, Krawczyk N, Solomayer EF et al. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 2008; 10: R76.
  • 27
    Hoefnagel LD, Moelans CB, Meijer SL et al. Prognostic value of estrogen receptor alpha and progesterone receptor conversion in distant breast cancer metastases. Cancer 2012; 118: 492935.
  • 28
    Hoon DS, Kitago M, Kim J et al. Molecular mechanisms of metastasis. Cancer Metastasis Rev 2006; 25: 20320.
  • 29
    Husemann Y, Geigl JB, Schubert F et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13: 5868.
  • 30
    Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 27484.
  • 31
    Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 13142.
  • 32
    Demicheli R, Ardoino I, Boracchi P et al. Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast. BMC Cancer 2010; 10: 656.
  • 33
    Demicheli R, Biganzoli E, Boracchi P, Greco M, Retsky MW. Recurrence dynamics does not depend on the recurrence site. Breast Cancer Res 2008; 10: R83.
  • 34
    Chambers AF, Goss PE. Putative growth characteristics of micrometastatic breast cancer. Breast Cancer Res 2008; 10: 114.
  • 35
    Tjensvoll K, Oltedal S, Heikkila R et al. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome. BMC Cancer 2012; 12: 190.
  • 36
    Mathiesen RR, Borgen E, Renolen A et al. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res 2012; 14: R117.
  • 37
    Chong MH, Zhao Y, Wang J et al. The dynamic change of circulating tumour cells in patients with operable breast cancer before and after chemotherapy based on a multimarker QPCR platform. Br J Cancer 2012; 106: 160510.
  • 38
    Zhang L, Riethdorf S, Wu G et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012; 18: 570110.
  • 39
    Payne RE, Wang F, Su N et al. Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients. Br J Cancer 2012; 106: 17907.
  • 40
    De Giorgi U, Mego M, Scarpi E et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer 2012; 12: 2649.
  • 41
    Lorusso G, Ruegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol 2012; 22: 22633.
  • 42
    Spano D, Heck C, De Antonellis P, Christofori G, Zollo M. Molecular networks that regulate cancer metastasis. Semin Cancer Biol 2012; 22: 23449.
  • 43
    Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 158.
  • 44
    Naumov GN, Folkman J, Straume O. Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis 2009; 26: 5160.
  • 45
    De Bock K, Mazzone M, Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 2011; 8: 393404.
  • 46
    Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett 2010; 294: 13946.
  • 47
    Sachdev JC, Jahanzeb M. Evolution of bevacizumab-based therapy in the management of breast cancer. Clin Breast Cancer 2008; 8: 40210.
  • 48
    Dienstmann R, Ades F, Saini KS, Metzger-Filho O. Benefit-risk assessment of bevacizumab in the treatment of breast cancer. Drug Saf 2011; 35: 1525.
  • 49
    Iyer V, Klebba I, McCready J et al. Estrogen promotes ER-negative tumor growth and angiogenesis through mobilization of bone marrow-derived monocytes. Cancer Res 2012; 72: 270513.
  • 50
    Gupta PB, Proia D, Cingoz O et al. Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res 2007; 67: 206271.
  • 51
    Maxwell PH, Dachs GU, Gleadle JM et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94: 81049.
  • 52
    Carmeliet P, Dor Y, Herbert JM et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 48590.
  • 53
    Pugh CW, Gleadle J, Maxwell PH. Hypoxia and oxidative stress in breast cancer Hypoxia signalling pathways. Breast Cancer Res 2001; 3: 3137.
  • 54
    Chaturvedi P, Gilkes DM, Wong CC et al. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Invest 2013; 123: 189205.
  • 55
    Schito L, Rey S, Tafani M et al. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci USA 2013; 109: E270716.
  • 56
    Krishnamachary B, Penet MF, Nimmagadda S et al. Hypoxia regulates CD44 and its variant isoforms through HIF-1alpha in triple negative breast cancer. PLoS ONE 2013; 7: e44078.
  • 57
    Montagner M, Enzo E, Forcato M et al. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature 2013; 487: 3804.
  • 58
    Neumeister VM, Sullivan CA, Lindner R et al. Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer. Breast Cancer Res Treat 2013; 136: 6775.
  • 59
    Tuomela J, Sandholm J, Karihtala P et al. Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer. Breast Cancer Res Treat 2013; 135: 48193.
  • 60
    Walker RA. The complexities of breast cancer desmoplasia. Breast Cancer Res 2001; 3: 1435.
  • 61
    Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392401.
  • 62
    Bateman A, Bennett HP. The granulin gene family: from cancer to dementia. BioEssays 2009; 31: 124554.
  • 63
    Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 2007; 102: 85968.
  • 64
    Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363: 193848.
  • 65
    Curtis RE, Freedman DM, Ron E. et al (eds). New malignancies Among Cancer Survivors: SEER Cancer Registries, 1973‒2000. National Cancer Institute, NIH pubi. No. 05-5302 Bethesda, MD, 2006.
  • 66
    Muller V, Riethdorf S, Rack B et al. Prognostic impact of circulating tumor cells assessed with the Cell Search AssayTM and AdnaTest BreastTM in metastatic breast cancer patients: the DETECT study. Breast Cancer Res 2012; 14: R118.
  • 67
    Hannemann J, Meyer-Staeckling S, Kemming D et al. Quantitative high-resolution genomic analysis of single cancer cells. PLoS ONE 2011; 6: e26362.
  • 68
    Powell AA, Talasaz AH, Zhang H et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE 2012; 7: e33788.
  • 69
    Rack B, Juckstock J, Gunthner-Biller M et al. Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Arch Gynecol Obstet 2011; 285: 48592.
  • 70
    Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 51827.
  • 71
    Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012; 23: 140315.
  • 72
    Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol 2012; 30: 346877.
  • 73
    Sim SH, Messenger MP, Gregory WM et al. Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma. Br J Cancer 2012; 107: 11317.
  • 74
    Thoms JW, Dal Pra A, Anborgh PH et al. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. Br J Cancer 2012; 107: 8406.
  • 75
    Liersch R, Shin JW, Bayer M et al. Analysis of a novel highly metastatic melanoma cell line identifies osteopontin as a new lymphangiogenic factor. Int J Oncol 2012; 41: 145563.
  • 76
    Shojaei F, Scott N, Kang X et al. Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J Exp Clin Cancer Res 2012; 31: 26.
  • 77
    Cheung ST, Wong SY, Leung KL et al. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin Cancer Res 2004; 10: 762936.
  • 78
    Howlader N, Noone AM, Krapcho M et al. eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute, 2011.
  • 79
    Olson EM, Najita JS, Sohl J et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast 2013; doi: 10.1016/j.breast.2012.12.006.
  • 80
    Livi L, Bonomo P, Meattini I et al. Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience. Med Oncol 2013; 30: 434.
  • 81
    Fan Y, Xu BH, Yuan P et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol 2013; 24: 121925.